A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors

JS Weber, NJ Vogelzang, MS Ernstoff… - Journal of …, 2011 - journals.lww.com
Preferentially expressed antigen in melanoma (PRAME) and prostate-specific membrane
antigen (PSMA) are tumor-associated antigens implicated in cellular differentiation, genetic
stability, and angiogenesis. MKC1106-PP is an immunotherapeutic regimen cotargeting
PRAME and PSMA, comprised of a recombinant plasmid (pPRA-PSM encoding fragments
derived from both antigens) and 2 peptides (E-PRA and E-PSM derived from PRAME and
PSMA, respectively). This multicenter study evaluated MKC1106-PP with a fixed plasmid …